Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer

July 16, 2018
Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …

News
shutterstock

FDA approves first smallpox therapy to defend against bioterrorism

July 16, 2018
Sales and Marketing FDA, pharma, smallpox

The FDA has announced that it has awarded marketing authorisation to SIGA Technologies’ TPOXX (tecovirimat) in the first approval of …

News
medicinal_cannabis_uk_review

European cannabis market set to be worth €115.7 billion by 2028

July 16, 2018
Sales and Marketing Europe, Legislation, cannabis, medicinal marijuana

The European cannabis market is set to be worth €115.7 billion by 2028, according to a report released by the …

News

Indivior shares soar as US judge rules against Dr Reddy

July 16, 2018
Sales and Marketing

Shares in the London listed addiction specialist Indivior surged in price today, as the Indian pharmaceutical company Dr Reddy’s Laboratories …

News
gsk_boronia_australia

GSK confirms £250m deal to sell experimental drug to Dermavent Sciences

July 13, 2018
Medical Communications Dermavent, GSK, Roivant, tapinarof

British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ …

News
johnson_and_johnson_jj

J&J ordered to pay $4.68 billion to talc-powder plaintiffs

July 13, 2018
Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder

A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …

News

Alvogen court case causes Nevada Judge to halt execution

July 13, 2018
Medical Communications Alvogen, Nevada, court, execution, lethal injection

A Nevada Judge has temporarily prevented the use of the sedative midazolam, in the execution of the twice convicted killer …

News
takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma

July 12, 2018
Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, Pfizer, Sanofi, Trump, top 10

In the week leading up to Donald Trump’s visit to the United Kingdom, the news has been dominated by the …

News
shutterstock_273326141

Otsuka snaps up Visterra in $430 million deal

July 12, 2018
Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma

Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …

News

AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial

July 12, 2018
Research and Development AbbVie, Cancer, FDA, Janssen, approval

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …

News

Pfizer restructures in preparation for potential sell off

July 12, 2018
Sales and Marketing Pfizer, bisoimilar, consumer, health

Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from …

News
novartis_window

Novartis pulls out of antibiotics, cuts 140 staff

July 12, 2018
Sales and Marketing Antibiotics, Novartis, pharma, staff cuts

Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that …

News

NICE approves treatment for rare and deadly childhood cancer

July 11, 2018
Sales and Marketing Cancer, NICE, UK, neuroblastoma, pharma

NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form …

News
celgene_building

Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3

July 11, 2018
Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma

Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …

News
westminster-parliament-resized

UK Government announces £10m antimicrobial resistance research competition

July 11, 2018
Research and Development 10 million, antimicrobial, competition, government, resistance

The UK Government’s Department of Health and Social Care has announced the launch of a £10 million research competition aimed …

News
28246711066_52e38bc591_z

EMA survey identifies gaps in pharma industry’s preparedness for Brexit

July 11, 2018
Research and Development CAPS, EEA, EMA, brexit, preparedness

An EMA survey has identified gaps in the pharmaceutical industry’s preparedness for Brexit, finding that only 58% of market authorisation …

News

Wellcome Trust announces £250m fund for high risk ideas

July 11, 2018
Research and Development 250 million, Wellcome, britain, leap fund, pharma

The London-based biomedical research charity the Wellcome Trust, Britain’s wealthiest foundation, has announced the launch of a new £250 million …

News
shutterstock_254160583

Trump forces Pfizer to back down and delay price hikes until 2019

July 11, 2018
Research and Development, Sales and Marketing Alex Azar, Donald Trump, Ian Read, Pfizer, President trump, Trump, druig pricing, pharma

Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the …

News
mario_saltarelli_cropped

Syntimmune appoints Pfizer, AbbVie veteran as new CMO

July 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune

The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …

Appointment
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026